DiNABIOS is the trusted guide through the valley of translation¹ in drug development. Unlike others, we don't focus on the research, but on the researcher. To make their journey from lab to life not only possible but effortless.
DiNABIOS is the trusted guide through the valley of translation¹ in drug development. Unlike others, we don't focus on the research, but on the researcher. To make their journey from lab to life not only possible but effortless.
The ‘Valley of translation’ refers to the challenging phase of turning laboratory research into practical, clinical applications.
Our values
The principles we live and innovate by
Organic
Dynamic
Analytic
The DiNAQUBETM, our proprietary solution which helps you measure and analyze human-based 3D tissue. With ease
Our Story
Here’s to the curious
Our Purpose
Refers to the critical gap between scientific discovery and its development into marketable products, where many promising ideas fail to advance due to various challenges.
Our Vision
Our history
30 years of shaping the human tissue landscape for others to follow
1997
The first publication on EHTs⁴ laid the foundation for what would become a major advance in cardiac research.
FASEB Eschenhagen et al. 1997
2001
The first patent in the field of cardiac tissue engineering was secured, reflecting a commitment to innovative cardiac solutions.
2010
Publication on 24-well EHTs and video-optical recordings⁵ marked an improvement in the scalability of cardiac tissue research.
Circ Res Hansen, Eder et al. 2010
2011
Breakthrough with human embryonic stem cell-derived EHTs reported⁶, setting the stage for future therapeutic applications.
PLoS One Schaaf et al. 2011
2015
Based on the pioneering spirit of the industry, EHT Technologies GmbH was founded to advance the applications of EHT research.
2016
Research expanded with a publication on human-induced pluripotent stem cell-derived EHTs⁷, enriching the field of cardiac safety and efficacy testing.
Stem Cell Reports Mannhardt et al. 2016
2020
Joining forces with DiNAQOR AG sets the stage for expanded development and reach in cardiac tissue engineering.
2022
DiNAQUBE™ was introduced to change the landscape of cardiac research, offering new ways to measure and analyze heart tissue.
2023
As part of the DiNAQOR Group, DiNABIOS was established as an independent business group to further specialize in cutting-edge screening and phenotyping services and life science tools.
The team
Meet the minds behind the technology
- Core team
- Board & management
- Alexandra Rhoden, PhDHead Research & TechnologyMarcel Grunert, PhDHead Data & Business OperationsRobin SchönenbergerCFO, Head Corporate &
Business SupportReto WittwerChairman of the BoardThomas Eschenhagen, MDBoard of DirectorsChristina Baldauf, PhDHead of OperationsChandan Kadur, PhDSenior ScientistNouara ImhofResearch AssociateAna GameiroTechnical AssistantCordula GrüttnerTechnical AssistantMalte Loos, PhDProduction ScientistRukiye DedeProduction AssistantMohammad Nour NakkarProduction AssistantLisa HeinrichsdorffBusiness Support & Human ResourcesReto EberhardAccountingAndrew HartmannITBjörn JoachimLegal - Alexandra Rhoden, PhDHead Research & TechnologyAlexandra Rhoden, PhDHead Research & TechnologyAlexandra Rhoden, PhDHead Research & TechnologyAlexandra Rhoden, PhDHead Research & TechnologyAlexandra Rhoden, PhDHead Research & TechnologyAlexandra Rhoden, PhDHead Research & TechnologyAlexandra Rhoden, PhDHead Research & TechnologyAlexandra Rhoden, PhDHead Research & Technology
Let us be your trusted guide in drug development
Your data with DiNABIOS is as secure as DNA in a double helix. Check out our Privacy Policy for the specifics.